AstraZeneca PLC (AZN)
Automate Your Wheel Strategy on AZN
With Tiblio's Option Bot, you can configure your own wheel strategy including AZN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol AZN
- Rev/Share 18.5878
- Book/Share 14.7006
- PB 6.226
- Debt/Equity 0.7118
- CurrentRatio 0.8792
- ROIC 0.121
- MktCap 283267792806.0
- FreeCF/Share 3.5646
- PFCF 25.412
- PE 30.3966
- Debt/Assets 0.2854
- DivYield 0.0171
- ROE 0.218
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 4
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | AZN | Jefferies | -- | Buy | -- | -- | Oct. 27, 2025 |
| Downgrade | AZN | Deutsche Bank | Hold | Sell | -- | -- | Oct. 16, 2025 |
| Initiation | AZN | Exane BNP Paribas | -- | Outperform | -- | $75 | April 15, 2025 |
| Upgrade | AZN | UBS | Neutral | Buy | -- | -- | Feb. 13, 2025 |
| Initiation | AZN | Morgan Stanley | -- | Overweight | -- | -- | Feb. 12, 2025 |
| Downgrade | AZN | Deutsche Bank | Hold | Sell | -- | -- | Sept. 13, 2024 |
News
AZN, Daiichi's Enhertu Gets Breakthrough Tag for Expanded Cancer Use
Published: December 22, 2025 by: Zacks Investment Research
Sentiment: Positive
AstraZeneca's Enhertu wins FDA Breakthrough tag for expanded use in breast cancer, while a late-stage study on ceralasertib + Imfinzi in lung cancer misses its goal.
Read More
AstraZeneca Drug Combination Falls Short of Goal in Lung-Cancer Trial
Published: December 22, 2025 by: WSJ
Sentiment: Negative
The pharmaceutical company said its ceralasertib combination didn't meet the primary goal of a late-stage clinical trial for advanced lung cancer.
Read More
AstraZeneca's ceralasertib-Imfinzi combo misses survival target in lung cancer trial
Published: December 22, 2025 by: Reuters
Sentiment: Negative
AstraZeneca said on Monday that a late‑stage trial testing Imfinzi in combination with ceralasertib failed to improve overall survival in patients with previously treated advanced non‑small cell lung cancer.
Read More
This year's biotech laggards primed for 2026 recovery, says Goldman Sachs' Richter
Published: December 19, 2025 by: CNBC Television
Sentiment: Neutral
CNBC's “Closing Bell Overtime” team discusses why the biotech recovery may continue into 2026 with Salveen Richter, lead U.S. biotech analyst at Goldman Sachs Research.
Read More
Trump to announce new drug-pricing deals later today
Published: December 19, 2025 by: Market Watch
Sentiment: Positive
The White House is getting ready to announce more deals with drugmakers aimed at lowering drug prices.
Read More
AZN, Daiichi's Enhertu Gets FDA Nod for First-Line Breast Cancer
Published: December 16, 2025 by: Zacks Investment Research
Sentiment: Positive
AstraZeneca's Enhertu wins FDA nod as a first-line treatment for HER2-positive metastatic breast cancer.
Read More
Here's Why Astrazeneca (AZN) is a Strong Growth Stock
Published: December 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
AstraZeneca: A Rare Compound Growth Opportunity In Biopharma
Published: December 10, 2025 by: Seeking Alpha
Sentiment: Neutral
AstraZeneca (AZN) offers a rare, secular growth profile in biopharma, underpinned by a diversified commercial asset base and layered patent expirations. AZN faces a minor patent cliff, with most key products' loss of exclusivity in the 2030s, and rapidly growing therapies offsetting near-term risks. The pipeline is robust and diversified, targeting 20 new molecular entities by 2030, supporting management's ambition to nearly double revenues to $80B.
Read More
AZN's Baxdrostat Gets FDA Priority Tag for Uncontrolled Hypertension
Published: December 03, 2025 by: Zacks Investment Research
Sentiment: Positive
AstraZeneca's NDA for baxdrostat gains FDA priority review for treating hard-to-control hypertension. A decision is due in the second quarter of 2026.
Read More
Why Astrazeneca (AZN) is a Top Momentum Stock for the Long-Term
Published: December 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Baxdrostat New Drug Application accepted under FDA Priority Review in the US for patients with hard-to-control hypertension
Published: December 02, 2025 by: Business Wire
Sentiment: Neutral
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca's New Drug Application (NDA) for baxdrostat has been accepted for Priority Review by the US Food and Drug Administration (FDA) in the US for the treatment of adult patients with hard-to-control (uncontrolled or treatment resistant) hypertension as an add-on to other antihypertensive medicines when these do not provide adequate lowering of blood pressure. The Prescription Drug User Fee Act (PDUFA) date is anticipated during the second quarter of 202.
Read More
Here's Why Astrazeneca (AZN) is a Strong Growth Stock
Published: November 28, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
AstraZeneca or Merck: Which Oncology Giant Has the Edge?
Published: November 27, 2025 by: Zacks Investment Research
Sentiment: Positive
AZN and MRK boast major oncology strengths and expanding pipelines amid shifting market dynamics in this pharma matchup.
Read More
Why Astrazeneca (AZN) is a Top Value Stock for the Long-Term
Published: November 27, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Why Medicare price negotiations matter for Novo Nordisk, AstraZeneca, and other European pharma companies
Published: November 26, 2025 by: CNBC
Sentiment: Neutral
The IRA from 2022 allows the CMS to negotiate prices for a number of drugs each year for patients in Medicare. Late Tuesday, the agency announced newly negotiated prices for 15 blockbuster drugs from 2027, including Novo Nordisk's mega bestseller Ozempic which will see a 71% discount to its list price.
Read More
AstraZeneca Doubles Down On US Biologics Buildout As Drug Discovery Partnership Grows
Published: November 24, 2025 by: Benzinga
Sentiment: Positive
Hong Kong-based Harbour BioMed announced on Sunday an update and advancement of its global strategic collaboration with AstraZeneca Plc (NASDAQ: AZN), initially established in March 2025.
Read More
AstraZeneca to invest $2 billion as part of US manufacturing push
Published: November 21, 2025 by: Reuters
Sentiment: Positive
AstraZeneca said on Friday it will invest $2 billion to expand its manufacturing footprint in Maryland as part of its previously announced $50 billion plan to expand manufacturing and research capabilities in the U.S. by 2030.
Read More
AstraZeneca plans $2 billion manufacturing investment in Maryland, supporting 2,600 jobs and catalyzing economic growth
Published: November 21, 2025 by: Business Wire
Sentiment: Neutral
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announces plans to invest $2 billion to expand its long-standing manufacturing footprint in Maryland. This includes a significant expansion of its flagship biologics manufacturing facility in Frederick and construction of a new state-of-the-art facility in Gaithersburg for the development and clinical supply of innovative molecules to be used in clinical trials. The investment will support 2,600 jobs across the two sites in the state includin.
Read More
AZN Wins FDA Nod for Expanded Use of Rare Disease Drug, Koselugo
Published: November 21, 2025 by: Zacks Investment Research
Sentiment: Positive
AstraZeneca secures FDA approval to expand Koselugo's use to treat adult NF1 patients with inoperable PN.
Read More
Biopharma companies have confidence in their ability to do deals: BMO's Evan Seigerman
Published: November 14, 2025 by: CNBC Television
Sentiment: Positive
Evan Seigerman, BMO Capital Markets head of health care research, joins 'Power Lunch' to discuss what's behind the recent move in health care stocks, the state of play with GLP-1s and much more.
Read More
Why Astrazeneca (AZN) is a Top Growth Stock for the Long-Term
Published: November 12, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
AstraZeneca's Investigational Hypertension Drug Shows Significant Blood Pressure Control In Pivotal Trial
Published: November 10, 2025 by: Benzinga
Sentiment: Positive
AstraZeneca Plc (NASDAQ:AZN) shared on Monday full data from the Bax24 Phase 3 trial of once-daily 2mg baxdrostat versus placebo, on the reduction of ambulatory systolic blood pressure (SBP), as well as safety and tolerability in participants with resistant hypertension.
Read More
AstraZeneca: Solid Results, But Risks Emerge (Rating Downgrade)
Published: November 06, 2025 by: Seeking Alpha
Sentiment: Negative
The highlight of AstraZeneca's latest results is the maintained full-year outlook despite the recent US drug pricing agreement. AstraZeneca's financials remain robust, with double-digit revenue and EPS growth, but Q4 2025 is expected to show slower or even negative EPS growth. Risks could also stem from U.S. pricing pressures and potentially unresolved tax issues in China. Additionally, stretched valuations and limited near-term upside, prompt a Hold rating.
Read More
AZN Q3 Earnings Top Estimates, Sales Rise As Most Key Drugs Outperform
Published: November 06, 2025 by: Zacks Investment Research
Sentiment: Positive
AstraZeneca posts strong Q3 results. Core earnings and revenues beat estimates as key drugs like Tagrisso, Imfinzi and Farxiga fuel broad-based growth.
Read More
AstraZeneca climbs to net all-time high after US deal reassurance
Published: November 06, 2025 by: Proactive Investors
Sentiment: Positive
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) posted what analysts called a very solid set of third-quarter results, but the shares barely moved in early morning trading as the City waited for more details on the analyst call. In afternoon trading, shares in the giant drugmaker jumped over 4% to a new all time high above 12,990p.
Read More
Compared to Estimates, Astrazeneca (AZN) Q3 Earnings: A Look at Key Metrics
Published: November 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Although the revenue and EPS for Astrazeneca (AZN) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Read More
AstraZeneca wins shareholder backing for NYSE listing in US pivot
Published: November 03, 2025 by: Reuters
Sentiment: Positive
AstraZeneca shareholders approved a direct listing of the drugmaker's shares on the New York Stock Exchange on Monday, giving it access to a deeper capital pool.
Read More
AstraZeneca wins shareholder backing for NYSE listing as drugmaker pivots to US
Published: November 03, 2025 by: Reuters
Sentiment: Positive
AstraZeneca shareholders approved a direct listing of the drugmaker's shares on the New York Stock Exchange on Monday, giving it access to a deeper capital pool.
Read More
BioInvent to Present Early Phase 2a Data from Ongoing Trial with Triple Combination of BI-1206, Rituximab, and Calquence in r/r NHL, at ASH 2025
Published: November 03, 2025 by: Accesswire
Sentiment: Neutral
LUND, SE / ACCESS Newswire / November 3, 2025 / BioInvent International AB ("BioInvent")(STO:BINV)(Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced that it will present new data from the safety run-in portion of its ongoing trial evaluating BI-1206 in combination with rituximab and Calquence ® (acalabrutinib) for the treatment of non-Hodgkin's lymphoma (NHL) in a poster at the upcoming 2025 American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, Florida. Abstract data (as of August 4, 2025) published in the November …
Read More
AstraZeneca to face questions on Trump MFN deal, patent expiries and pipeline
Published: October 31, 2025 by: Proactive Investors
Sentiment: Neutral
When AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) reports third-quarter results next Thursday, 6 November, with investors and analysts will be keen to hear about the financial implications of the 'most favoured nation' (MFN) pricing deal recently agreed with Donald Trump, as well as the loss of its Farxiga patent and prospects for new drugs coming out of its pipeline. This will be the first opportunity for discussion of the US MFN deal, making its a key discussion point, according to analysts at UBS.
Read More
About AstraZeneca PLC (AZN)
- IPO Date 1993-05-12
- Website https://www.astrazeneca.com
- Industry Drug Manufacturers - General
- CEO Pascal Claude Roland Soriot
- Employees 94300